Understanding the effects of living with COVID-19 and the treatment with nirmatrelvir-ritonavir.
Real World Evaluation of COVID-19 Burden and Nirmatrelvir/Ritonavir in Taiwan Using National Health Insurance Research Database
This study is trying to see how living with COVID-19 affects people and whether the medication nirmatrelvir-ritonavir helps them feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1 (estimated) |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06085924 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effects of living with COVID-19 and the effectiveness of the medication nirmatrelvir-ritonavir in treating the virus. It involves two groups of COVID-19 patients in Taiwan: one group includes patients of all ages diagnosed between January 2021 and December 2021, while the second group consists of participants aged 12 and older diagnosed between January 2022 and December 2022. The study will analyze the nature of COVID-19 disease and the experiences of those receiving treatment, helping to identify patients who may require hospitalization and understand severe outcomes associated with the infection.
Who should consider this trial
Good fit: Ideal candidates include individuals of all ages diagnosed with COVID-19 during the specified time frames.
Not a fit: Patients without a confirmed diagnosis of COVID-19 will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the treatment of COVID-19 and help improve patient management strategies.
How similar studies have performed: Other studies have shown success in evaluating COVID-19 treatments, making this approach relevant and potentially beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Cohort 1: Inclusion Criteria: * Patients of all ages * Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021 * Cases of patients registered in the databases Exclusion Criteria: * Patients without COVID-19 diagnosis Cohort 2: Inclusion Criteria: * ≥12 years of age * Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022 Exclusion Criteria: * Patients without COVID-19 diagnosis
Where this trial is running
Taipei
- Pfizer Limited — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.